BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114

Reuters12-05

BRIEF-<a href="https://laohu8.com/S/AMLX">Amylyx Pharmaceuticals</a> Announces New Safety And Tolerability Cohort 1 Data Of Amx0114

Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:

AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABILITY COHORT 1 DATA OF AMX0114 IN ALS FROM FIRST-IN-HUMAN LUMINA TRIAL
AMYLYX PHARMACEUTICALS INC - AMX0114 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Source text: ID:nBw68TDlNa

Further company coverage: AMLX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589818522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589818522","market":"us","top_or_hot":-1,"title":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 </title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>Amylyx Pharmaceuticals Inc <span>AMLX.O</span>:</p><ul><li><p>AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABILITY <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 1 DATA OF AMX0114 IN ALS FROM FIRST-IN-HUMAN LUMINA TRIAL</p></li><li><p>AMYLYX PHARMACEUTICALS INC - AMX0114 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>ID:nBw68TDlNa</span></p><p>Further company coverage: <span>AMLX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 </title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>Amylyx Pharmaceuticals Inc <span>AMLX.O</span>:</p><ul><li><p>AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABILITY <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 1 DATA OF AMX0114 IN ALS FROM FIRST-IN-HUMAN LUMINA TRIAL</p></li><li><p>AMYLYX PHARMACEUTICALS INC - AMX0114 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>ID:nBw68TDlNa</span></p><p>Further company coverage: <span>AMLX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:1","article_id":"2589818522","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589818522","pubTimestamp":1764943311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AMLX":"Amylyx Pharmaceuticals"},"translate_title":"简报-Amylyx Pharmaceuticals公布Amx0114新的安全性和耐受性队列1数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9},"content_text":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABILITY COHORT 1 DATA OF AMX0114 IN ALS FROM FIRST-IN-HUMAN LUMINA TRIALAMYLYX PHARMACEUTICALS INC - AMX0114 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSSource text: ID:nBw68TDlNaFurther company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589818522","isCrawlerRequest":true}